Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Estimated Useful Life of Assets

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:

	Estimated Useful Life
Manufacturing equipment	5 years
OCS Consoles loaned to customers	5 years
Computer equipment and software	3 years
Laboratory equipment	3 years
Office and trade show equipment	5 years
Leasehold improvements	Shorter of term of lease or 15 years

Schedule of Recognized Revenue Net of Payments

The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):

	Fiscal Year Ended
	December 31,		December 28,
	2020		2019
Gross revenue from sales to customers	$	28,356	$	25,844
Less: Clinical trial payments reducing revenue		2,717		2,240
Total net revenue	$	25,639	$	23,604

Schedule of Net Revenue by OCS Product and Country

The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

	Fiscal Year Ended
	December 31,		December 28,
	2020		2019
Net revenue by OCS product:
OCS Lung net revenue	$	6,194	$	8,664
OCS Heart net revenue		14,196		11,442
OCS Liver net revenue		5,249		3,498
Total net revenue	$	25,639	$	23,604

	Fiscal Year Ended
	December 31,		December 28,
	2020		2019
Net revenue by country (1):
United States	$	19,239	$	16,253
All other countries		6,400		7,351
Total net revenue	$	25,639	$	23,604

(1) Net revenue by country is categorized based on the location of the end customer.

Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:

	As of
	December 31, 2020		December 28, 2019
Warrants to purchase common stock		64,440		64,440
Options to purchase common stock		2,261,234		1,952,300
Employee stock purchase plan		14,951		—
		2,340,625		2,016,740